Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Rift Valley Fever

Rift Valley Fever — NIH Grants & Funding

Active and recent NIH-funded research on Rift Valley Fever. Data from NIH RePORTER, last 36 months.

MONDO:0017880

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Rift Valley Fever has active NIH research funding with 14 funded grants totaling $90.9M.

14funded grants from NIH

Portfolio: $83.0MCumulative: $90.9M10 active4 completed11 PIs7 institutions

2 new grants started in the last 12 months.

By Research Theme

Basic Science

Translational

Clinical

Epi / Nat. History

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$80.1M

FY22

$2.5M

FY23

$3.1M

FY24

$4.6M

FY25

$656K

FY26

By Funding Mechanism

R01

R21

F31

F32

K08

R41

Funding Gap Analysis

Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Rift Valley Fever. Strongest funded area: Basic Science. Largest gap: Biomarker / Diagnostics.

Biomarker / DiagnosticsPublished, Not NIH-Funded

18 publications in Diagnostic / Biomarker but no NIH-funded grants found in Biomarker / Diagnostics for Rift valley fever. Existing research activity suggests this may be a viable area for grant applications.

Adjacent Research(5 grants)

These grants mention Rift Valley Fever as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(5)

OtherU19Active

Machine learning-enabled design of prototype pathogen vaccines and antibodies

King, Neil et al.·UNIVERSITY OF WASHINGTON·SEATTLE, WA

$41,075,241 (FY2024)

NIH RePORTER

OtherN01Completed

B cell Epitope Discovery and Mechanisms of Antibody Protection for Enterovirus and Bunyavirus Entry Proteins

Unknown PI·INTEGRAL MOLECULAR·PHILADELPHIA, PA

$1,722,325 (FY2025)

NIH RePORTER

OtherR01Active

Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses

Amarasinghe, Gaya et al.·WASHINGTON UNIVERSITY·SAINT LOUIS, MO

$767,375 (FY2025)

NIH RePORTER

OtherR56Completed

Comparative Analysis of Bunyavirus Neuropathogenesis

Hartman, Amy·UNIVERSITY OF PITTSBURGH AT PITTSBURGH·PITTSBURGH, PA

$1,149,175 (FY2022)

NIH RePORTER

OtherR41Completed

Development of recombinant VSV vaccines for emerging bunyaviruses

Bates, Paul et al.·ADVAC THERAPEUTIC, LLC·Phoenixville, PA

$276,715 (FY2024)

NIH RePORTER

NIH Grants & Funding for Rift Valley Fever | Kisho | Kisho

Kisho

Rift Valley Fever — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Funding Gap Analysis

Adjacent Research(5 grants)

Other(5)

Machine learning-enabled design of prototype pathogen vaccines and antibodies

B cell Epitope Discovery and Mechanisms of Antibody Protection for Enterovirus and Bunyavirus Entry Proteins

Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses

Comparative Analysis of Bunyavirus Neuropathogenesis

Development of recombinant VSV vaccines for emerging bunyaviruses

Top Funded Institutions

Top Principal Investigators